1. Generics Bulletin
  2. >>Business
  3. >>Deals

Dr Reddy’s Snaps Up Wockhardt’s Branded Generics Business

Long-Awaited Transaction Sees Wockhardt Sell Business For $260m

 
• By Anju Ghangurde

Financially stretched Wockhardt sells select branded generic business to Dr Reddy’s for $260m, bringing the curtains down on a much anticipated transaction.

M&A
Dr Reddy's acquires Wockhardt's branded Generics business • Source: Shutterstock

Wockhardt has divested parts of its branded generics business in India and certain international territories to Dr Reddy's Laboratories for INR18.50bn ($260m), ending long-running speculation around an imminent deal that is expected to help the Mumbai-based firm pare debt and provide liquidity for its remaining operations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.